Is STEP 5 a fair comparison of semaglutide against its comparator arm?

The specifics, since they change the answer: STEP 5 · semaglutide.

I would like to know whether this claim survives contact with evidence.

If the answer is "nobody has tested that", I would like that stated so I can stop looking.

Is this actually true, and what is the evidence?

Fair depends on the comparator arm, and in STEP 5 that means asking whether the comparator was titrated to the same ambition as the experimental one. A head-to-head that runs its comparator to a dose below the one it is licensed at is not measuring the two agents, it is measuring one agent against a handicapped version of the other. Check three things: the maximum comparator dose reached, the proportion of the comparator arm that reached it, and whether the titration schedules had the same duration. If those match, the comparison is fair on dosing and the argument moves to the endpoint. If they do not, the effect size is partly an artefact of the protocol.

Answer first: read the primary endpoint, the comparator and the population before you read the effect size. Almost every argument on this site about a trial is really an argument about one of those three.

Intention-to-treat and per-protocol analyses answer different questions. ITT asks what happens if you offer the treatment; per-protocol asks what happens if it is taken as directed. The gap between the two is a measure of how tolerable the protocol was.

To be exact about it, placebo arms in this class are not nothing. Lifestyle-intervention placebo arms in the major obesity trials commonly lose two to three per cent of body weight, so an active-arm figure quoted without its comparator overstates the drug effect by roughly that much.

The caveat is that trial evidence is about licensed product administered under supervision. None of it transfers automatically to research-grade material of unverified content.

Read the protocol and the statistical analysis plan if the result matters to you. Both are usually published alongside.

In practice, a trial establishes what happened to a defined group under a defined protocol. Extending it beyond that group is inference, and inference is allowed as long as it is labelled.

Confidence intervals matter more than point estimates when two trials disagree. Two studies reporting fifteen and twenty per cent whose intervals overlap heavily have not disagreed about anything.

Open-label extensions are not the same evidence as the randomised phase. Once everyone knows what they are taking, the reported outcomes acquire a bias that no analysis fully removes.

Registry entries at ClinicalTrials.gov carry the pre-specified primary endpoint with a timestamp, which is the cheapest available check on whether an endpoint was changed after the data were seen.

I am not a clinician and this is not medical advice; it is a reading of a published protocol.

Quote the interval alongside the estimate and half the disagreements on this site would not start.

Start with what the trial was powered for. Everything else in the publication is secondary, exploratory, or a subgroup, and those three words mean three different things.

Trial populations are selected. Exclusion criteria in this class routinely remove people with significant renal impairment, prior pancreatitis and unstable psychiatric illness, which is exactly the population the results are then quoted for.

In practice, duration decides what can be seen. A 68-week trial can measure weight and glycaemia; it cannot measure anything whose event rate is one per cent per year without enrolling tens of thousands.

Be careful about generalising from a trial population to yourself. The exclusion criteria are usually the most informative page in the supplement.

If a claim cannot be traced to a named trial with a named endpoint, treat it as a claim rather than as evidence.

edited 5 Apr 2025 by Dr_Elias_Weiss — clarified the distinction between purity and content

On the detail: this is answerable from the published record, but only if you take the placebo arm seriously rather than reading the active arm alone.

Non-inferiority and superiority designs are not interchangeable. A non-inferiority result says the new agent is not meaningfully worse against a pre-specified margin — it does not say it is as good, and it certainly does not say it is better.

Meta-analyses in this area are dominated by whichever trial contributed the most participants, so read the forest plot rather than the summary estimate.

The short version: check the endpoint, check the comparator, check who was excluded, then look at the number.

Put another way, the trial answers a narrower question than the headline suggests, and the narrowing is where the useful information is.

A composite endpoint is only as informative as its least serious component. Where a cardiovascular composite combines death, infarction and stroke, ask which component moved, because they are not interchangeable outcomes.

The cardiovascular outcome programme in this class runs to several large randomised trials — LEADER for liraglutide, SUSTAIN-6 and SELECT for semaglutide, REWIND for dulaglutide — and they are the reason the class is discussed as more than a weight intervention.

When two sources disagree, the answer is almost always in the methods section of the one you have not read.